key: cord-0035836-czqzsppq
authors: Donaldson, Braeden; Al-Barwani, Farah; Young, Vivienne; Scullion, Sarah; Ward, Vernon; Young, Sarah
title: Virus-Like Particles, a Versatile Subunit Vaccine Platform
date: 2014-08-28
journal: Subunit Vaccine Delivery
DOI: 10.1007/978-1-4939-1417-3_9
sha: a065f219244a30fbfe0008ab3ca4ebb2a535a34d
doc_id: 35836
cord_uid: czqzsppq

Virus-like particles (VLPs) can be spontaneously formed after expression of self-polymerising viral capsid proteins. VLPs structurally resemble their native source virus, maintaining immunological relevance by retaining formation of immunogenic motifs with natural conformation. The absence of the virus genome renders VLPs safe for administration as a subunit vaccine. VLPs can target both arms of the immune response, with some VLPs initiating production of specific antibodies and others activating cytotoxic T cells. VLPs are also exceptionally versatile, conferring protection against the host virus or acting as a scaffold for antigenic molecules. In addition, VLP can support intraparticulate encapsulation for immunomodulation and gene delivery. VLP vaccines have been developed for prophylactic protection against infectious organisms, and therapeutic treatment of conditions such as Alzheimer’s disease, hypertension, and cancer. With an expanding list of vaccine candidates, VLP vaccines are a promising field with a wide range of applications.

Novel vaccine development requires a balance between eliciting a potent immune response while limiting the unintentional induction of hypersensitivity and offtarget effects. Virus-like particles (VLPs) are a form of subunit vaccine consisting of self-assembling shells derived from virus capsid proteins. Due to the absence of viral genomic material, VLPs are rendered non-replicative and non-infectious, enhancing their safety profi le. In comparison to other subunit vaccines, the resemblance of VLPs to their corresponding native virus provides enhanced immunogenicity and specifi city. VLP capsid proteins retain their natural structural conformation, harbouring undamaged antigenic motifs in a more immunologically relevant state than an inactivated virus vaccine. VLPs can also resemble a live attenuated virus without replicative or infectious capacity due to structural similarity and utilisation of similar processing pathways. In general, VLPs are considered significantly safer than many other virally derived vaccines by avoiding potential hazards such as attenuated virus reversion or incomplete inactivation.

The fi rst VLP identifi ed and studied was isolated from patients infected with Hepatitis B virus (HBV) in 1968 (Bayer et al. 1968 ). Due to the ability of some viral capsid proteins to spontaneously form stable particles, many viruses produce VLPs as a natural by-product of their infection cycle. Engerix (GlaxoSmithKline) was the fi rst human VLP-based vaccine, licensed in 1989 for vaccination against HBV. Since then a number of VLP vaccines have been approved for clinical use, including Epaxal (Crucell) for Hepatitis A virus (HAV), Recombivax (Merck), Hepavax (Crucell), and many others for HBV, Gardasil (Merck), and Cervarix (GlaxoSmithKline) for human papillomavirus (HPV), and Infl exal V (Crucell) for Infl uenza. Bolstered by the success of these vaccines many new VLPs are being developed, with a selection of examples summarised in Table 9 .1 . In addition, VLPs have also been produced from various non-human mammalian viruses, primarily for vaccination of livestock. Examples include porcine circovirus (Kim et al. 2002 ) , bovine rotavirus (Rodriguez-Limas et al. 2011 ), chicken anaemia virus (Noteborn et al. 1998 ; Koch et al. 1995 ) , SARS coronavirus (Liu et al. 2011 ) , Nipah virus (Walpita et al. 2011 ) , and swine vesicular stomatitis virus (Ko et al. 2005 ).

Spontaneous polymerisation of a range of viral capsid proteins can yield VLPs with authentic geometric symmetry, usually icosahedral, spherical or rod-like in shape, depending on the source virus. VLPs can be generally categorised into groups based on their structural complexity, including single-protein non-enveloped (e.g. VLPs derived from caliciviruses (Jiang et al. 1992 ) , papillomaviruses (Kirnbauer et al. 1992 ) , and parvoviruses (Lopez de Turiso et al. 1992 ) ), multi-protein non-enveloped (e.g. VLPs derived from infectious bursal disease virus (Kibenge et al. 1999 ), poliovirus (Brautigam et al. 1993 ) , and reoviruses ) and enveloped VLPs (e.g. VLPs derived from Hantaan virus (Betenbaugh et al. 1995 ) , hepatitis C virus (Baumert et al. 1998 ) , infl uenza A (Latham and Galarza 2001 ) , and retroviruses (Yamshchikov et al. 1995 ) ) as illustrated in Fig. 9 .1 . While single-protein VLPs have a relatively simple structure, multi-protein VLPs can contain unique structural features such as several distinct capsid layers. For example, expression of various combinations of the VP2, VP4, VP6, and VP7 capsid proteins of rotavirus can produce stable VLPs with double or even triple capsid layers (Crawford et al. 1994 ; Sabara et al. 1991 ) .

Multi-protein VLPs can also be produced from variant copies of the same protein derived from different viral strains. These mosaic VLPs effi ciently confer protection against several strains of the same virus (Buonamassa et al. 2002 ). An alternative means of increasing VLP versatility is through the incorporation of antigens from heterologous sources. Chimeric VLPs contain antigenic material from a target source supported by a stable VLP framework. These antigens can be inserted as peptides into the VLP capsid protein or substructural secondary VLP proteins, or covalently coupled to the surface of VLP. Chimeric VLPs have an extensive range of potential applications, and will be discussed later in this chapter. Enveloped VLPs consist of either a single-protein or multi-protein VLPs encapsulated in a lipid bilayer captured from the cell membrane. Co-expression of haemagglutinin (HA), neuraminidase (NA), matrix protein M1, and ion channel protein M2 from infl uenza virus produces enveloped VLPs with the same size and morphology as native infl uenza virions, including the characteristic surface spikes HA and NA (Latham and Galarza 2001 ) . The lipid bilayer of enveloped VLPs can also support the incorporation of transmembrane anchored proteins from multiple viral strains (enveloped mosaic VLPs) or even heterologous pathogens (enveloped chimeric VLPs) (Buonaguro et al. 2001 ; Halsey et al. 2008 ; Visciano et al. 2011 ) . VLP structural complexity appears to have few limitations, with intriguing novel constructs still frequently theorised and investigated.

VLPs are a natural by-product produced during the infection cycle of certain viruses (Bayer et al. 1968 ). The same characteristics that benefi t effi cient virus reproduction, such as spontaneously polymerising capsid proteins, also promote the Fig. 9 .1 VLP Structure. VLPs can be categorised based on characteristic structural features such as capsid protein composition, encapsulation inside a lipid bilayer envelope, and incorporation of antigens by recombinant insertion or chemical conjugation. Additional combinations other than those illustrated also exist, such as multi-protein chimeric VLPs and enveloped mosaic or chimeric VLPs formation of VLPs; however, the isolation of VLPs produced from virally infected cells is not an effi cient means of purifi cation. An expansive range of protein expression systems have been developed for a variety of applications, and can be effectively commandeered for the production and purifi cation of high quality VLPs. Recombinant expression of viral capsid proteins through tailored expression systems can also enable the production of VLPs from viruses not routinely cultured in laboratories. Common VLP expression systems include bacteria, yeast, insect cell lines, mammalian cell lines, plants, and cell-free cultures. Each expression system has its benefi ts and pitfalls as outlined in Table 9 .2 (Rebeaud and Bachmann 2012 ) . While most VLPs can be produced in multiple expression systems, the quaternary structural conformation of the capsid proteins produced can vary due to differences in post-translational modifi cations such as phosphorylation and glycosylation. This can have signifi cant effects on the immunogenicity of VLPs, as these modifi cations are often essential for eliciting the desired immune response. Escherichia coli ( E. coli ) has long been a primary laboratory workhorse bacterium, facilitating the expression and purifi cation of recombinant proteins through plasmid transformation or bacteriophage vector delivery. Expression in E. coli is often preferred when producing small proteins with limited post-translational modifi cations; however, larger proteins with post-translational modifi cations require a more complex expression system (e.g. Chinese hamster ovary (CHO) mammalian cell line). The presence of endotoxins during downstream purifi cation also presents a signifi cant challenge for vaccine development from a bacterial expression system. Each VLP is unique, with optimal expression identifi ed through trial and error by comparing the translated products of multiple expression systems. For example, Rabbit Haemorrhagic Disease Virus (RHDV) VLPs can be optimally produced by expressing the RHDV VP60 capsid protein in Spodoptera frugiperda (SF) cells using a recombinant baculovirus vector (Young et al. 2004 (Young et al. , 2006 Peacey et al. 2007 ). Icosahedral T = 3 VLPs with a diameter of around 40 nm spontaneously form when VP60 is expressed in SF21 cells. Each VLP contains 180 copies of the VP60 capsid protein, representing a relatively simple single-protein non-enveloped VLP. These VLPs structurally resemble native RHDV virions, as illustrated in Fig. 9 .2 (Katpally et al. 2010 ; Wang et al. 2013 ) .

Production of VLPs in transgenic plants (e.g. tobacco, potato, tomato) is a relatively new concept with interesting applications. Expression of recombinant proteins in plants is achieved through transgene insertion into the nuclear or plastid genome, or using plant viral vectors. While plant cells do not have a mammalianlike post-translational modifi cation system, plant-specifi c glycosylation can have an immunostimulatory effect. Some examples of VLPs produced in a transgenic plant system include Norwalk virus (Tacket 2007 ; Tacket et al. 2000 ) , HIV-1 (Scotti et al. 2009 ), and infl uenza virus VLPs (Medicago) . Another recently developed expression platform is the cell-free system. This usually consists of extracts from E. coli or yeast cells, and was developed primarily to enable the production of viral capsid proteins which have toxic intermediate protein forms. Development of VLPs containing unnatural amino acids (UAAs) has also been achieved using the cell-free system. The non-replenishing nature of a cell-free system renders this method highly demanding with some scalability limitations. The infl uenza vaccine Rebeaud and Bachmann ( 2012 ) Infl exal V (Herzog et al. 2009 ), and the hepatitis A vaccine Epaxal (Bovier 2008 ) (Crucell) are two commercialised VLP vaccines that consist of virosomes produced in a cell-free expression system. Following production, VLPs must be isolated from the expression system and purifi ed to suffi cient quality for downstream applications. VLPs are usually isolated through a combination of cell lysis, removal of cellular debris, VLP concentration, and selective purifi cation. Some mammalian and insect cell lines secrete VLPs into the supernatant, negating the necessity for cell lysis (Vicente et al. 2011 ). Resilient cells (e.g. bacteria, plant cells) may require more robust mechanical manipulation such as ultrasonication, compression, abrasion, repeated freeze/thawing, or enzymatic (Katpally et al. 2010 ) degradation for VLP release (Cull and McHenry 1990 ; Salazar and Asenjo 2007 ) . VLPs can be purifi ed by differential centrifugation; however, this can pose limitations on scalability. GMP production of vaccine-grade purifi ed VLPs for commercial applications often involves industrial-scale protein purifi cation methods such as sizeexclusion, ion exchange, or affi nity chromatography columns (Vicente et al. 2011 ) . Optimal solvent conditions must also be identifi ed to maintain VLP stability. Solution pH is critical, as some VLPs irreversibly denature and disassemble beyond a specifi c pH range. For example, RHDV VLPs deteriorate in an alkaline environment, with complete VLP disruption above pH 9 ( Fig. 9 .3 ). VLP solubility is another important consideration as some VLPs may aggregate at higher concentrations, forming an insoluble precipitate.

VLPs are an incredibly versatile vaccination tool. In addition to harbouring multiple copies of immunologically recognisable antigens from their source virus, VLPs can also be used as a nanoparticulate delivery vector for heterogenous antigenic molecules. Each VLP can be considered a polymerised protein subunit vaccine, Fig. 9 .3 RHDV VLP stability at an alkaline pH. RHDV VLPs are visibly perturbed under transmission electron microscopy in an elevated solvent pH, resulting in irreversible particle disassembly supporting modifi cations such as recombinant peptide insertion and chemical conjugation of peptides, proteins, lysate, carbohydrates, and lipoproteins to form chimeric VLPs. Some VLPs can support insertion of short peptide sequences at specifi c sites in their structural capsid proteins without impairing VLP formation. For example, RHDV VP60 is known to retain its ability to spontaneously form VLPs despite recombinant insertion of peptides at the N-terminus, C-terminus, or at amino acid residue 306 (Crisci et al. 2009 ); however, these sites have restrictions on inserted peptide length and residue sequence. The N-terminus of RHDV VP60 can support an insertion of <33 amino acids (Peacey et al. 2007 ) , while other viral proteins such as polyomavirus VP1 can support insertions ranging from 9 to 120 amino acids (Eriksson et al. 2011 ; Lasickiene et al. 2012 ; Mazeike et al. 2012 ; Middelberg et al. 2011 ) . Inclusion of secondary capsid proteins, such as polyomavirus VP2, with a limited contribution to VLP stability, can support large insertions including truncated proteins (Tegerstedt et al. 2005 ) . HBV core antigen (HBcAg) has been one of the most popular VLP forming viral capsid proteins for recombinant insertion of immunogenic epitopes. Notable recombinant HBc vaccines include Malariavax, which targets Plasmodium falciparum ( P. falciparum ); the protozoan responsible for malaria (Gregson et al. 2008 ) , and a pan-infl uenza A vaccine against the infl uenza matrix protein 2 (M2e) ectodomain universally conserved between strains (Fiers et al. 2009 ). The phase I clinical trial of the recombinant infl uenza A M2e vaccine ACAM-FLU-A reported a 90 % seroconversion rate amongst participants after two vaccinations, with no severe adverse side-effects observed (Fiers et al. 2009 ).

Recombinant non-mammalian VLPs can also be used to deliver immunogenic peptides derived from mammalian pathogens. Various plant viruses have demonstrated promise as recombinant antigen scaffolds, including alfalfa mosaic virus (AlMV) VLP containing epitopes from HIV-1 or rabies virus (Yusibov et al. 2002 ) , cowpea mosaic virus (CPMV) VLP containing epitopes from Bacillus anthracis (Phelps et al. 2007 ) or HPV16 (Matic et al. 2011 ) and tobacco mosaic virus (TMV) VLP containing epitopes for P. falciparum (Turpen et al. 1995 ) . The potential applications of chimeric VLPs extend far beyond the incorporation of epitopes from mammalian pathogens. VLPs containing auto-antigens naturally present in humans have been harnessed for a variety of novel roles, such as targeting angiotensin II to combat hypertension (Ambuhl et al. 2007 ; Maurer and Bachmann 2010 ) , targeting Aβ protein to treat Alzheimer's disease (Zamora et al. 2006 ; Wiessner et al. 2011 ; Chackerian et al. 2006 ) , or interrupting cytokine signalling pathways (Spohn et al. 2008 ; Link and Bachmann 2010 ) . VLPs that stimulate an immune response against nicotine have even been investigated for their potential to break smoking addiction (Maurer et al. 2005 ; Cornuz et al. 2008 ) . The therapeutic application of VLPs can also be used to develop novel vaccines for cancer. For example, recombinant insertion of a truncated form of Her2 protein into polyomavirus VP1/VP2 VLP confers protection against Her2 positive mammary carcinoma (Tegerstedt et al. 2005 ) .

The selected site of recombinant insertion in chimeric VLP provides an inherent limitation on vaccine applications. Recognition of native unprocessed antigen is an essential component of B cell activation in the humoral immune system leading to antibody production. Internal site insertion prevents such interactions, and restricts these sites to insertion of antigenic epitopes that utilise intracellular processing pathways. External site insertion is required for effective B cell activation and depending on the selected VLP this method of chimeric VLP design can have signifi cantly increased complexity. While internal site insertions are typically cloned onto an internal terminus of the VLP capsid protein, external site insertion requires in-depth understanding of the capsid protein quaternary structure and the interactions between each protein subunit to identify the optimal site for insertion. For example, the RHDV VP60 capsid protein is arranged with its N-terminus facing internally and C-terminus facing externally; however, the quaternary structural conformation has the C-terminus folded backwards into the central protein bulk. Amino acid 306 of RHDV VP60 capsid protein was instead identifi ed as a potential external insertion site for exposure of immunogenic peptides tailored for B cell recognition (Crisci et al. 2009 ).

An alternative means of avoiding the limitations imposed by recombinant peptide insertion is to utilise VLPs as a particulate scaffold for chemical conjugation of antigenic molecules such as peptides, proteins, lysate, carbohydrates, and lipoproteins. Advancement in coupling chemistry continues to expand the list of viable conjugation candidates, primarily limited by their effects on the resulting particles size, solubility, and processing. Conjugation uses a chemical linker as a bridge, commonly conjugating proteins by acylation of amino groups, alkylation of sulfhydryl groups, or the activation of carboxylic acid residues. Some of the most commonly used protein coupling chemistries are illustrated in Fig. 9 .4 (Smith et al. 2013 ). Azide-alkyne click chemistry (Patel and Swartz 2011 ) and biotin-streptavidin complexes (Chackerian et al. 2008 ) are also used in VLP conjugation. Heterobifunctional crosslinkers have two reactive groups enabling effi cient protein crosslinking; however, this has the unfortunate side-reaction of non-specifi c conjugation, which can result in protein aggregation in a complex solution such as tumour lysate. Bioorthogonal crosslinkers are a specifi c alternative that enables selective conjugation, limiting side-reactions by targeting chemical motifs absent in biological systems (e.g. phosphines).

Chemical conjugation of immunogenic peptides is a relatively simple alternative to recombinant insertion, using commercial protein crosslinkers such as Sulfo-SMCC (Thermo Fisher Scientifi c Inc., Rockford, IL, USA). Sulfo-SMCC is a heterobifunctional crosslinker which permits a stepwise conjugation process targeting the amino groups on the VLP surface (NHS-ester) and the sulfhydryl group (maleimide group) from a cysteine residue introduced at the N-terminus of a target epitope (Peacey et al. 2008 ) . Direct comparison between recombinant insertion and chemical conjugation of an H2k b -restricted peptide from lymphocytic choreomeningitis virus (LCMV) gp33 in chimeric RHDV VLP indicated that the recombinant form induced a superior in vivo cytotoxic response (Li et al. 2013 ) . Remarkably both the coupled and recombinant forms induced 20 % and 50 % tumour-free survival, respectively, following a single vaccination without adjuvant in mice grafted with Lewis' lung carcinoma tumours expressing gp33. The addition of a 4 week vaccination boost with VLP and adjuvant increased tumour-free survival to 70 % in mice vaccinated with the recombinant gp33 RHDV VLP (Li et al. 2013 ).

Conjugation of large proteins or cell lysate onto the surface of VLPs enables the induction of an immune response without identifi cation of specifi c immunogenic peptides. Tumour lysates derived from the MART-1 expressing melanoma cell line Mel888 conjugated onto RHDV VLP provides more effi cient lysate delivery to dendritic cell antigen processing compartments and enhances MART-1-specifi c CD8+ T cell stimulation compared to lysate alone (Win et al. 2012 ) . The use of tumour lysate in VLP vaccines has potential applications for personalised anti-cancer immunotherapy. Fig. 9 .4 Chemical conjugation onto the surface of VLPs. Various molecules can be coupled onto the surface of VLPs through chemical conjugation, targeting primary amines (e.g. lysine, N-termini), thiols (e.g. cysteine), carboxylic acids (e.g. glutamic acid, aspartic acid), and phenols (e.g. tyrosine). Unnatural amino acids (UAAs) incorporated into the structure of VLPs can also be used as potential chemical conjugation targets by introducing reactive azide or alkyne groups. Adapted from Smith et al ( 2013 ) 

Although VLPs are devoid of genomic material from their source virus, they are not necessarily always empty. Many viral structural proteins have an inherent ability to bind specifi c nucleic acids, facilitating packaging of the viral genome during the infection cycle. This property is retained in some VLPs and can be appropriated for encapsulation of negatively charged molecules such as oligonucleotides and chemical polymers. The primary limitations on intraparticulate encapsulation are the VLPs internal cavity volume and the availability of positively charged amino acids (Zeltins 2013 ) . VLPs with the ability to encapsulate exogenous DNA have been explored as a possible means of gene delivery. VLPs produced from the VP1 capsid protein of the human polyomavirus John Cunningham (JC) virus are a promising candidate, with the ability to harbour DNA plasmids up to 14 kbp in length (Fang et al. 2012 ). Delivery of pEGFP-C1 plasmid into human epithelial kidney 293 (HEK293) cells and subsequent EGFP production was achieved by loading the plasmid into JC virus VLPs through osmotic shock, which disrupts the VLP structure and increases permeability (Ou et al. 1999 ) . More recently in vivo plasmid loading during expression of VP1 in E. coli was found to result in superior plasmid loading over osmotic shock or VLP reassembly, validated with JC virus VLPs encapsulating pEGFP-N3 plasmid ). This loading method was subsequently used with pUMVC1-tk plasmid containing the herpes simplex virus thymidine kinase (tk) suicide gene. JC virus VLPs containing pUMVC1-tk were found to selectively target human colon carcinoma (COLO-320 HSR) cells grafted in nude mice, significantly reducing tumour volume following administration of ganciclovir .

Chimeric VLPs have also been used to encapsulate DNA plasmids, enabling successful gene delivery upon cellular uptake. Recombinant insertion of the DNA binding site from HPV type 16 (HPV-16) L1 (VP60Δ-L1BS) or L2 (VP60Δ-L2BS) capsid protein onto the N-terminus of RHDV VP60 produces chimeric VLPs with the capacity to encapsulate pCMV-β in vitro through VLP reassembly. β-Galactosidase expression was identifi ed in a range of cell lines (Cos-7, R17, HuH-7, and CaCo 2 ) treated with VP60Δ-L1BS containing pCMV-β plasmid (El Mehdaoui et al. 2000 ) . It is possible that any VLP that supports internal site insertion may be capable of DNA plasmid encapsulation and delivery by incorporation of an appropriate DNA binding site. VLPs have even been used to induce the expression of their own structural capsid protein, enhancing immunogenicity by mimicking viral replication in vivo (Pichlmair et al. 2010 ) . A variety of molecules other than nucleic acids have also been successfully encapsulated into VLPs, including enzymes into Qβ VLPs (Fiedler et al. 2010 ) , polymerase into rotavirus VLPs (Boudreaux et al. 2013 ) , and fl uorophores into cucumber mosaic virus VLPs (Lu et al. 2012 ) . Recombinant insertion of a heterodimeric coiled-coil amino acid motif at the N-terminus of a capsid protein from cowpea chlorotic mottle virus (CCMV) produced CCMV VLPs capable of encapsulating up to 15 EGFP proteins (Minten et al. 2009 ). Encapsulating exogenous proteins inside VLPs is an interesting concept with multiple potential therapeutic applications.

The immune response to VLP vaccines is primarily determined by particle size, capsid structure, and innate immunity activation. Particles larger than 200 nm require transportation to the lymph nodes by peripheral antigen presenting cells (APCs) at the vaccination site (e.g. macrophages, dendritic cells) (Manolova et al. 2008 ) . VLPs are usually below 200 nm, facilitating free circulation and drainage directly to lymph nodes in addition to peripheral APC transportation. Once in the lymph node, free VLPs are internalised by resident APCs. The repetitive structure of VLPs promotes effi cient uptake by APCs through mechanisms such as phagocytosis and macropinocytosis (Win et al. 2011 ; Xiang et al. 2006 ; Scheerlinck and Greenwood 2008 ) . Due to VLPs consisting of native viral capsid proteins, they often contain receptor binding motifs that also enable receptor-mediated endocytosis. An example of this is the binding of haemagglutinin in infl uenza VLPs to the sialylose receptor on the cell surface (Pan et al. 2010 ) .

The processing of VLPs by APCs can lead to the stimulation of both the humoral and cell-mediated arms of the immune system. Historically vaccines have been designed to target the initiation of humoral immunity, generating vaccine-specifi c antibodies. While this type of immune response is essential for the clearance of extracellular pathogens, establishing protection against intracellular conditions such as viral infections and cancer often requires the generation of cell-mediated immunity. The ability of VLPs to stimulate both arms of the immune system is advantageous, as the combination of immune responses often work synergistically to ensure disease clearance and the initiation of effective immunological memory. The immune response to VLPs is summarised in Fig. 9 .5 .

Following internalisation VLPs are degraded and processed through the exogenous antigen processing pathway with immunogenic peptides loaded onto MHC class II (MHC-II) molecules for surface presentation. Processed antigens are recognised by CD4 + T helper cells, resulting in activation and release of immunostimulatory cytokines, such as Interleukin (IL) 4, IL-5, which are essential for B cell activation or IL-2 and IFNγ, which are essential for induction of cell-mediated immunity. For successful activation of the humoral immune system, B cells must also interact with native antigen through B cell receptors (BCRs). The repetitive nature of VLPs promotes crosslinking of BCRs, enhancing activation and promoting memory-cell formation. This stimulation is notably superior to soluble peptides or non-repetitive proteins (Jegerlehner et al. 2007 ; Bachmann and Jennings 2010 ) . Antibodies produced in response to VLPs can neutralise native virions to prevent active infection, and memory-cell formation promotes long-term immunity. Notable examples of licensed VLP vaccines that successfully induce high titres of longlasting neutralising antibodies include the Hepatitis B vaccine Engerix (Keating and Noble 2003 ) and the HPV vaccines Cervarix and Gardasil (Romanowski 2011 ) .

Some VLPs are also cross-presented by APCs, primarily CD8 + dendritic cells, facilitating loading of exogenous antigen onto MHC class I (MHC-I). With additional stimulation from co-stimulatory molecules (e.g. CD40, CD80/86), MHC-I loaded with immunogenic peptides can activate CD8 + T cells to initiate a cellmediated immune response. Cytotoxic T lymphocyte (CTL) activation is advantageous for clearance of intracellular conditions such as viral infection or cancer. For example, RHDV VLPs are processed through the receptor-recycling pathway for cross-presentation. Immunogenic peptides are loaded onto MHC-I when phagolysosomes containing degraded VLPs fuse with endosomes containing MHC-I molecules recycling from the cell surface (Win et al. 2011 ) . The endosomes return to the cell surface, displaying new MHC-peptide complexes on the cell membrane as illustrated in Fig. 9 .6 .

The site of vaccine administration can play an important role in VLP immunogenicity. As the mucosal membranes (e.g. respiratory tract, digestive tract, urogenital tract) are a common route of infection, generation of mucosal immunity can provide early protection against pathogenic intrusion. A number of preclinical VLP vaccine trials have demonstrated that VLPs have the ability to initiate potent mucosal immunity. For example, intranasal vaccination with cholera toxin B conjugated to simian immunodefi ciency virus VLPs signifi cantly increased the (Win et al. 2011 ) . Adapted from Groothuis and Neefjes ( 2005 ) levels of antibody detected in the mucosae compared to unconjugated cholera toxin B (Kang et al. 2003 ) .

Depending on the protein expression system used, some VLPs can contain exogenous immunogenic molecules such as bacterial RNA which promote APC activation through stimulation of pattern recognition receptors such as toll-like receptors (TLRs) (Rebeaud and Bachmann 2012 ) . This can have an adjuvanting effect due to activation of the innate immune system; however, we have found that successful vaccination can be achieved in the absence of these adjuvanting molecules (Li et al. 2013 ) . RHDV VLPs produced in insect cell cultures do not stimulate innate cells cultured in vitro, but effectively activate the cell-mediated and humoral immune systems in vivo. Despite the success of VLP vaccination alone, the inclusion of an adjuvant can still be benefi cial in driving specifi c immune pathway activation and leading to further enhancement of immune stimulation.

A number of adjuvants have been used in humans; these include mineral salts (e.g. aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphates), emulsions (e.g. MF59, AS01, and AS02), and microbial derivatives (monophosphoryl lipid A and CpG) (Rappuoli et al. 2011 ) . Traditionally adjuvants were used to enhance vaccine immunogenicity by stimulating the humoral immune system to induce antibody production and isotype-switching. This was thought to be facilitated by formation of a slow-release antigen depot. Modern adjuvants are designed to directly target immune activation and to tailor vaccination to drive a specifi c immune response, enabling selective stimulation of the cell-mediated immune system. TLR agonists such as unmethylated CpG DNA can induce a potent cell-mediated response by stimulating upregulated expression of co-stimulatory molecules in innate immune cells. We have found that the addition of CpG to recombinant RHDV VLP containing the SIINFEKL peptide derived from the model antigen OVA (VLP.OTI) led to an enhancement in the generation of SIINFEKL-specifi c cytotoxic T cells (Fig. 9 .7 ) (Scullion 2012 ) . This association was also confi rmed using the Lewis' lung carcinoma model with recombinant gp33 RHDV VLP (Li et al. 2013 ). Co-delivery of vaccine adjuvants and antigens to cells through physical association or linkage leads to enhanced immunogenicity and a reduction in adjuvant-related side effects. Viruses often bind molecules that facilitate entry into host cells. RHDV VLPs retain the ability of its native virus to bind carbohydrate moieties, providing a useful mechanism for modifi cation and vaccine enhancement (Ruvoen-Clouet et al. 2000 ; McKee et al. 2012 ) . α-Galactosylceramide is a glycolipid adjuvant which was found to directly associate with RHDV VLP, forming a composite particle. α-Galactosylceramide activates natural killer-like T cells, leading to the enhancement of both the innate and acquired immune responses (Bendelac et al. 2007 ). Prophylactic vaccination with recombinant gp33. RHDV VLP and α-galactosylceramide led to the generation of gp33-specifi c T cells and enhanced protection against subcutaneous tumour challenge. The adjuvanting effect of α-galactosylceramide was increased >10-fold when delivered as a composite particle compared to the co-delivery of unassociated α-galactosylceramide and recombinant gp33.RHDV VLP (McKee et al. 2012 ).

The primary requirements of a successful vaccine include safety, reliability, and effi cacy. Along with other subunit vaccines VLPs have an impeccable safety record, with some vaccines already approved for routine use. The absence of the viral genome renders VLPs incapable of infection or replication, preventing inadvertent reversion as has occurred with attenuated viruses. Extensive purifi cation of VLPs Fig. 9.7 The effect of CpG adjuvant on in vivo cytotoxicity. Co-administration of RHDV VLP containing the SIINFEKL peptide (VLP. OTI) with CpG signifi cantly increased % specifi c lysis of target cells loaded with SIINFEKL peptide (Scullion 2012 ) produced using protein expression systems helps to limit contamination with substances which might induce allergies or undesirable side effects. Each new VLP is extensively characterised during development, containing immunogenic epitopes in a more natural state than inactivated virus vaccines. The particulate nature of VLPs also provides some protection from degradation. VLPs are uniform in structure, providing consistency between preparations and a reliable vaccine. VLPs are readily processed by the immune system and can stimulate cytotoxic and humoral immune responses. VLPs can provide protection against their source virus, or they can harbour exogenous antigens. This unprecedented versatility in vaccine design enables the utilisation of VLP vaccines in a wide range of applications including prophylactic viral vaccines, therapeutic cancer vaccines, and even gene delivery. VLP vaccines have only begun to unveil their true potential as a versatile subunit vaccine platform.

A vaccine for hypertension based on virus-like particles: preclinical effi cacy and phase I safety and immunogenicity

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

Hepatitis C virus structural proteins assemble into viruslike particles in insect cells

Particles associated with Australia antigen in the sera of patients with leukaemia, Down's syndrome and hepatitis

The biology of NKT cells

Safety and immunogenicity of a candidate parvovirus B19 vaccine

Nucleocapsidand virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus

Rotavirus core shell subdomains involved in polymerase encapsidation into virus-like particles

Recent advances with a virosomal hepatitis A vaccine

Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein

High effi cient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A

Yeast coexpression of human papillomavirus types 6 and 16 capsid proteins

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses

Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model

Effi cient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model

A vaccine against nicotine for smoking cessation: a randomized controlled trial

Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells

Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant

Preparation of extracts from prokaryotes

Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modifi ed DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues

Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor

Analysis of the size of DNA packaged by the human JC virus-like particle

RNA-directed packaging of enzymes within virus-like particles

M2e-based universal infl uenza A vaccine

Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV

Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein

The many roads to cross-presentation

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles

Eleven years of Infl exal V-a virosomal adjuvanted infl uenza vaccine

TLR9 signaling in B cells determines class switch recombination to IgG2a

Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein

Mucosal immunization with virus-like particles of simian immunodefi ciency virus conjugated with cholera toxin subunit B

High-resolution cryo-electron microscopy structures of murine norovirus 1 and rabbit hemorrhagic disease virus reveal marked fl exibility in the receptor binding domains

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective effi cacy against hepatitis B

Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells

Characterization of the recombinant proteins of porcine circovirus type2 fi eld isolate expressed in the baculovirus system

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay

Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus

Virus-like particles as a highly effi cient vaccine platform: diversity of targets and production systems and advances in clinical development

The use of recombinant pseudotype virus-like particles harbouring inserted target antigen to generate antibodies against cellular marker p16INK4A

Formation of wild-type and chimeric infl uenza virus-like particles following simultaneous expression of only four structural proteins

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Antigen incorporated in virus-like particles is delivered to specifi c dendritic cell subsets that induce an effective antitumor immune response in vivo

Immunodrugs: breaking B-but not T-cell tolerance with therapeutic anticytokine vaccines

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and infl uenza matrix 1 effi ciently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV

Recombinant vaccine for canine parvovirus in dogs

Safety and immunogenicity of a virus-like particle pandemic infl uenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

Encapsidation of DNA, a protein and a fl uorophore into virus-like particles by the capsid protein of cucumber mosaic virus

Nanoparticles target distinct dendritic cell populations according to their size

Effi cient production of chimeric human papillomavirus 16L1 protein bearing the M2e infl uenza epitope in Nicotiana benthamiana plants

Immunization against angiotensins for the treatment of hypertension

A therapeutic vaccine for nicotine dependence: preclinical effi cacy, and phase I safety and immunogenicity

Induction of insert-specifi c immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope

Virus-like particles and alpha-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses

Medicago receives authorization from health Canada and commences phase ii clinical trial for an H5N1 vaccine

A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines

Controlled encapsulation of multiple proteins in virus capsids

Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specifi c neutralizing epitope

The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells

Construction and characterization of insect cell-derived infl uenza VLP: cell binding, fusion, and EGFP incorporation

Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry

Versatile RHDV virus-like particles: incorporation of antigens by genetic modifi cation and chemical conjugation

Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects

Inactivation and purifi cation of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis

Virus-like particles expressing the nucleocapsid gene as an effi cient vaccine against Rift Valley fever virus

Vaccines for the twenty-fi rst century society

Virus-like particles as effi cient delivery platform to induce a potent immune response. In: Baschieri S (ed) Innovation in vaccinology: from design, through to delivery and testing

Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae

Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines

Binding of rabbit hemorrhagic disease virus to antigens of the ABH histo-blood group family

Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins

Enzymatic lysis of microbial cells

Virus-sized vaccine delivery systems

High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts

Investigating cytotoxic T cell responses to RHDV virus-like particles: a thesis submitted for the degree of Master of Science at the University of Otago

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

Plant-based vaccines against diarrheal diseases

Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors

Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus

Large-scale production and purifi cation of VLP-based vaccines

Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins

Vaccine potential of Nipah virus-like particles

Atomic model of rabbit hemorrhagic disease virus by cryo-electron microscopy and crystallography

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specifi c immune responses in patients with metastatic breast cancer: a phase I study

The secondgeneration active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects

Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles

Pathogen recognition and development of particulate vaccines: does size matter?

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

Novel vaccine formulations to enhance Type 1 immune responses

Transcutaneous vaccination with virus-like particles

Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine

Papillomavirus-like particles are an effective platform for amyloidbeta immunization in rabbits and transgenic mice

Construction and characterization of virus-like particles: a review